Professor of Clinical Oncology University of Leeds
David Sebag-Montefiore qualified at St Bartholomew’s Hospital, London and trained in clinical oncology at Middlesex, Mount Vernon and St Bartholomew’s Hospitals. He was subsequently appointed Consultant in Clinical Oncology in Leeds. In 2012, he took up his post as the Audrey and Stanley Burton Professor of Clinical Oncology at the University of Leeds. His research interests focus on improving outcomes for patients with gastrointestinal cancer using radiotherapy. He is a member of the National Cancer Research Institute Colorectal Study Anal and Rectal Group and the Clinical and Translational Radiotherapy Group (CTRad) and chair of the anal and rectal cancer subgroups until 2012. He is Chair of Cancer Research UK’s Clinical Trials Awards and Advisory Committee. Rectal cancer research interests include the
development of high quality multi-disciplinary management of rectal cancer through the MERCURY study group with a focus on the role of pelvic MRI staging and national training programmes such as the low rectal cancer educational courses (LOREC). He is Chief Investigator of the Medical Research Council CR07 rectal trial with recent publications in the Lancet and Journal of Clinical Oncology and the on-going phase III ARISTOTOLE trial testing the role of novel chemoradiation in MRI defined locally advanced rectal cancer. He also co-led the largest international trial in anal cancer (ACT2),is a member of the anal cancer International Rare Cancer Initiative (IRCI) and leads the PLATO anal cancer trials consortium.